FirstWord

BioMarin is combining Profluent's de novo protein design approach with its enzyme therapy expertise to identify potential candidates more efficiently.

Since its first mission launched in 2023, Varda has completed six reentry missions with over a dozen more launches and reentries planned through 2028.

The company said tulisokibart, designed to help address immuno-fibrosis, posted up to a 72% HiSCR50 response at week 16 in Phase II testing.

EloraTZP, a combination of eloralintide and tirzepatide, also cut A1c by up to 2.9% in adults with obesity and type 2 diabetes.

Roche and Zealand's amylin analogue showed weight loss peaked at the 5-mg dose, where patients achieved a 9.8% reduction.

Four oral presentations and three posters build upon Phase 3 ABTECT Maintenance and Induction programs in ulcerative colitis, long-term Phase 2 findings, and preclinical anti-fibrotic researchPARIS, F...

Data presented in Vienna demonstrate suppression of proinflammatory cytokines implicated in atopic dermatitis, supporting continued development of CTO1681 as an oral immunomodulatory therapy.PITTSBURG...

Executing a full strategic portfolio reset, RedHill is now a stronger commercial entity with Rebyota® and Clenpiq®, two established FDA-approved gastrointestinal (GI) brands that generated $37.5 milli...

-- Clinically meaningful efficacy data observed on primary and key secondary endpoints at Week 36 ---- Robust durability, including maintenance and deepening of response, observed following the 16-wee...

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or complete...